A significant biomanufacturing expansion project that just broke ground in Frederick, Colorado, about 30 miles north of Denver, adds another nine-figure development deal to the state’s rapidly growing life sciences sector.

Agilent Technologies Inc. kicked off construction on a $725M plant to manufacture nucleic acids therapeutics. The new 200K SF facility, an addition to existing facilities, is expected to open in 2026 to serve the region’s growing life sciences sector.

The addition at Eagle Business Park will be the latest for California-based Agilent, which entered the Colorado market in 2006 in Boulder. Local and state government provided roughly $11M in incentives for the facility, expected to produce 160 jobs.

According to CBRE, the Denver area has a 1M SF pipeline of life sciences projects and growing demand that often struggles to find suitable spaces.

The announcement of the Agilent deal comes after a big 2022 investment by BioMed Realty in Boulder, Colorado, a $625M deal for the 1M SF Flatiron Park, a 22-building campus near University of Colorado Boulder’s BioFrontiers Institute.